Eisai and TorreyPines Therapeutics Enter Into a New Alliance Contract Regarding a New Genetic Research Program for Alzheimer's Disease
Along with the conclusion of the research agreement signed in October 2002, between Eisai Co., Ltd (Headquarters: Tokyo, President & CEO: Haruo Naito) and TorreyPines Therapeutics, Inc. (Headquaters: California, USA, President & CEO: Neil Kurtz, M.D.) that focused on the discovery of genes responsible for LOAD (Late Onset Alzheimer's Disease); a new agreement was signed recently.
In this latest agreement, research program will focus on “unbiased genome-wide screening” of genes associated with Alzheimer's disease not depending on known biology including the beta-amyloid hypothesis, and enables to reveal the whole picture of the pathogenesis of the disease, as well as identifying genes associated with Alzheimer's disease from candidate genes discovered through the previous research collaboration. Eisai will hold exclusive rights of first negotiation and refusal for new gene targets discovered and validated through the research of TorreyPines Therapeutics, Inc.
Eisai has been committed to discover next generation treatment for Alzheimer's disease with multi-faced approarches targeted for production inhibition and antibody of beta-amyloid, that is believed to be responsible for the onset of Alzheimer's disease. Eisai further stepped into the novel remedy of the disease based on the genetic information. This new agreement will allow significant advance in search of the remedy.
TorreyPines Therapeutics is a biopharmaceutical company that discovers, develops and commercializes breakthrough small molecule drugs to treat diseases and disorders of the central nervous system. Through its own research, in-licensing and strategic coordination, the company is leveraging novel technologies to deliver new therapies for migraine, neuropathic pain and neurodegenerative disorders such as Alzheimer's disease.